# Phase 1 Neoplasm Metastasis trials recruiting: 163 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 163 trials in phase 1 for Neoplasm Metastasis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Neoplasm Metastasis trials: 163 rows for $8.15, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/neoplasm-metastasis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 163
- Recruiting or not yet: 163
- Read on: November 19, 2026

## Trials

The 25 newest of 163, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07940881 | A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SI-B037 in Solid Tumors | SystImmune Inc. | Phase 1 | Recruiting | Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, First in Human, Metastatic Solid... | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940881) |
| October 29, 2026 | NCT07903415 | A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors. | Pfizer | Phase 1 | Recruiting | Pancreatic Ductal Adenocarcinoma, Esophageal Cancer, Carcinoma, Non-Small-Cell Lung (NSCLC), Gastric Carcinoma... | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903415) |
| October 26, 2026 | NCT07893535 | An Investigational Study of BON-106 in Adults With Advanced or Metastatic Solid Tumors | BeOne Medicines | Phase 1 | Not yet recruiting | Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893535) |
| October 16, 2026 | NCT07878988 | This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic... | LTZ Therapeutics, Inc. | Phase 1 | Recruiting | Colorectal Cancer, Advanced/Metastatic Solid Tumor, Solid Tumor (Phase I), EPCAM, Colon Cancer | 152 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07878988) |
| September 18, 2026 | NCT07829185 | Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer | University of Oklahoma | Phase 1 | Recruiting | Pancreatic Ductal Adenocarcinoma (PDAC) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829185) |
| August 19, 2026 | NCT07772895 | Pemefolacianine for IMI of Lung Cancer | Sponsor not shown (see the record) | Phase 1 | Recruiting | Lung Cancer (Locally Advanced or Metastatic) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07772895) |
| August 4, 2026 | NCT07746141 | A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic... | BeOne Medicines | Phase 1 | Recruiting | RAS Mutation, Advanced Solid Tumor, Metastatic Solid Tumor | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07746141) |
| July 27, 2026 | NCT07728942 | SLR-108 PET Imaging in Subjects With Advanced Cancer | Solve Therapeutics | Phase 1 | Recruiting | Metastatic Solid Tumors | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07728942) |
| July 21, 2026 | NCT07715903 | Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump... | National Cancer Institute (NCI) | Phase 1 | Not yet recruiting | Colorectal Neoplasms, Neoplasms, Intrahepatic Cholangiocarcinoma, Adrenocortical Carcinoma, Metastasis, Neoplasm | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715903) |
| July 2, 2026 | NCT07681882 | First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors | Daiichi Sankyo | Phase 1 | Recruiting | Advanced Solid Tumor, Metastatic Solid Tumor, Unresectable Solid Tumor | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07681882) |
| June 18, 2026 | NCT07658196 | TLR9 Immunotherapy for Peritoneal Carcinomatosis | Brown University | Phase 1 | Recruiting | Malignant Ascites, Colorectal Adenocarcinoma, Peritoneal (Metastatic) Cancer, Appendiceal Adenocarcinoma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07658196) |
| June 10, 2026 | NCT07638371 | FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers | Memorial Sloan Kettering Cancer Center | Phase 1 | Recruiting | Solid Tumor, Solid Carcinoma, Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07638371) |
| May 28, 2026 | NCT07612176 | A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors | NEOK Bio, Inc. | Phase 1 | Recruiting | Locally Advanced (Unresectable) or Metastatic Solid Tumors | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07612176) |
| May 13, 2026 | NCT07584499 | Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors | Sun Yat-sen University | Phase 1 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma, Lymphoepithelial... | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07584499) |
| May 13, 2026 | NCT07583914 | Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors | West China Hospital | Phase 1 | Not yet recruiting | Solid Tumor Cancer, Metastases, Head and Neck Cancer | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583914) |
| May 13, 2026 | NCT07583654 | Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors | West China Hospital | Phase 1 | Recruiting | mRNA Vaccine, Solid Tumor Cancer, Peptides, Cancer Metastatic | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583654) |
| May 13, 2026 | NCT07583316 | A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A\*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors | Corregene Biotechnology Co., Ltd | Phase 1 | Not yet recruiting | Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC) | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583316) |
| May 4, 2026 | NCT07563829 | NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies | NextPoint Therapeutics, Inc. | Phase 1 | Recruiting | Metastatic Malignant Neoplasm | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07563829) |
| April 21, 2026 | NCT07543055 | A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and... | Regeneron Pharmaceuticals | Phase 1 | Recruiting | Prostate Cancer | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07543055) |
| April 13, 2026 | NCT07524140 | A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors | Eilean Therapeutics | Phase 1 | Recruiting | Advanced Solid Tumor Cancer, Metastatic Solid Tumor | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07524140) |
| April 8, 2026 | NCT07518654 | Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or... | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Leukaemia (Acute Lymphoblastic), Leukaemia (Acute Myeloid), Neuroblastoma, Neuroblastoma, Metastatic, Leukaemia... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07518654) |
| March 9, 2026 | NCT07458347 | A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral... | Kestrel Therapeutics, Inc. | Phase 1 | Recruiting | KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant... | 545 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07458347) |
| March 6, 2026 | NCT07455617 | Study of ABO2102 in KRAS-Mutated Solid Tumors | Suzhou Abogen Biosciences Co., Ltd. | Phase 1 | Recruiting | Advanced / Metastatic Solid Tumor | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07455617) |
| March 6, 2026 | NCT07454668 | Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases | Baptist Health South Florida | Phase 1 | Not yet recruiting | Breast Cancer, HER2-positive Breast Cancer, Brain Metastases, Cancer, Cancer Metastatic | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07454668) |
| March 6, 2026 | NCT07454031 | Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma | Peking University | Phase 1 | Not yet recruiting | Peritoneal (Metastatic) Cancer | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07454031) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 13 |
| City of Hope Medical Center | 4 |
| Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | 3 |
| Memorial Sloan Kettering Cancer Center | 3 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 3 |
| M.D. Anderson Cancer Center | 3 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 3 |
| MOMA Therapeutics | 2 |
| Erasca, Inc. | 2 |
| West China Hospital | 2 |
| TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 2 |
| Solve Therapeutics | 2 |
| NextPoint Therapeutics, Inc. | 2 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 2 |
| NiKang Therapeutics, Inc. | 2 |
| [Astellas Pharma Global Development, Inc.](https://specstream.ai/data/clinical-trials/company/astellas-pharma-global-development-inc) | 2 |
| University of Chicago | 2 |
| University of California, Davis | 2 |
| [Astellas Pharma Inc](https://specstream.ai/data/clinical-trials/company/astellas-pharma-inc) | 2 |
| IntoCell, Inc | 1 |
| Therorna | 1 |
| Baptist Health South Florida | 1 |
| [Jazz Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/jazz-pharmaceuticals) | 1 |
| Kestrel Therapeutics, Inc. | 1 |
| University of Oklahoma | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 114 |
| China | 30 |
| Australia | 18 |
| Spain | 15 |
| South Korea | 14 |
| Canada | 12 |
| France | 10 |
| Japan | 9 |
| United Kingdom | 8 |
| Taiwan | 7 |
| Italy | 5 |
| Belgium | 4 |
| Netherlands | 4 |
| Germany | 4 |
| Israel | 3 |
| Singapore | 2 |
| Puerto Rico | 2 |
| Denmark | 1 |
| Norway | 1 |
| Brazil | 1 |
| Austria | 1 |
| Hong Kong | 1 |
| Portugal | 1 |
| Sweden | 1 |
| Mexico | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [DUI law firms in the United States](https://specstream.ai/data/businesses/dui-law-firms/united-states)
- [Entertainment law firms in the United States](https://specstream.ai/data/businesses/entertainment-law-firms/united-states)
- [Fire protection companies in the United States](https://specstream.ai/data/businesses/fire-protection-companies/united-states)
- [Geriatric medicine practices in the United States](https://specstream.ai/data/businesses/geriatric-medicine-practices/united-states)
- [Home staging companies in the United States](https://specstream.ai/data/businesses/home-staging-companies/united-states)
- [Instrumentation engineers in the United States](https://specstream.ai/data/businesses/instrumentation-engineers/united-states)
